Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101138 | 1.00 | PIK3CB (0.36) | PIK3CBLTB4RKIF11PIK3CAPIK3CG | |
| SCHEMBL10101125 | 0.85 | PIK3CB (0.38) | PIK3CBLTB4RKIF11PIK3CAPIK3CG | |
| SCHEMBL10101251 | 0.81 | PIK3CB (0.35) | PIK3CBLTB4RKIF11PIK3CAPIK3CG | |
| SCHEMBL10101139 | 0.79 | PIK3CB (0.38) | PIK3CBPIK3CAPIK3CGALOX15ALOX12 | |
| SCHEMBL10101266 | 0.79 | PIK3CB (0.53) | PIK3CBPIK3CAPIK3CGALOX15ALOX12 | |
| SCHEMBL10101134 | 0.78 | PIK3CB (0.43) | PIK3CBPIK3CAPIK3CGALOX15ALOX12 | |
| SCHEMBL10101208 | 0.78 | PIK3CB (0.43) | PIK3CBPIK3CAPIK3CGALOX15ALOX12 | |
| SCHEMBL10101274 | 0.76 | PIK3CB (0.37) | PIK3CBLTB4RKIF11PIK3CAPIK3CG | |
| SCHEMBL10101267 | 0.76 | PIK3CB (0.37) | PIK3CBPIK3CAPIK3CGALOX15ALOX12 | |
| SCHEMBL10101120 | 0.75 | PIK3CB (0.40) | PIK3CBLTB4RKIF11PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101605-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PTPRO, PPM1G | PIK3CB 98/4885LTB4R 2603/4885KIF11 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.